

Applicant: Michael EISENHUT et al.
Application No. 09/781,980
Attorney Docket No. 2502498-991110
(formerly 41443)

IN THE CLAIMS:

1. (Amended) An oligonucleotide conjugate comprising: (a) an oligonucleotide at least part of whose sequence is complementary to an intracellular nucleic acid sequence; and (b) a somatostatin analog, wherein said (a) and (b) are conjugated by one or more covalent bonds.
2. (Original) The oligonucleotide conjugate according to claim 1, wherein the oligonucleotide is an oligodeoxyribonucleotide.
3. (Original) The oligonucleotide conjugate according to claim 1 or 2, wherein the phosphodiester compounds in the oligonucleotide are partially or fully replaced by phosphorothioate compounds.
4. (Previously Amended) The oligonucleotide conjugate according to claim 1, wherein the 3' end in the oligonucleotide is covalently bonded to a propanediol group.
5. (Previously Amended) The oligonucleotide conjugate according to claim 1, wherein the somatostain analog is octreotide or octreotate, or a derivative thereof.
6. (Previously Amended) The oligonucleotide conjugate according to claim 1, wherein the somatostain analog is covalently bonded to the 5' end of the oligonucleotide molecule.
7. (Previously Amended) The oligonucleotide conjugate according to claim 1, wherein the somatostain analog is covalently bonded to a base present in the oligonucleotide molecule via a spacer.

Applicant: Michael EISENHUT et al.
Application No. 09/781,980
Attorney Docket No. 2502498-991110
(formerly 41443)

8. (Original) The oligonucleotide conjugate according to claim 5 or 6, wherein the somatostain derivative is Tyr³ octreotide.

9. (Previously Amended) The oligonucleotide conjugate according to claim 1, wherein the intracellular nucleic acid sequence is an mRNA or viral RNA.

10. (Original) The oligonucleotide conjugate according to claim 9, wherein the intracellular nucleic acid sequence is the coding portion of an mRNA.

11. (Previously Amended) The oligonucleotide conjugate according to claim 1, wherein the oligonucleotide has a length of 8 to 50 nucleotides.

12. (Original) The oligonucleotide conjugate according to claim 11, wherein the oligonucleotide has a length of 12 to 20 nucleotides.

13. (Previously Amended) The oligonucleotide conjugate according to claim 1, wherein the oligonucleotide is partially complementary to the nucleic acid coding for the proto-oncogene bcl-2.

14. (Withdrawn)

15. (Previously Amended) The oligonucleotide conjugate according to claim 1, wherein the oligonucleotide is a peptide nucleic acid derivative (PNA).

16. (Previously Amended) The pharmaceutical preparation, containing the oligonucleotide conjugate according to claim 1, optionally in combination with a pharmaceutically compatible carrier.

17. (Amended) A method of antisense therapy, comprising administering the oligonucleotide defined according to claim 1 to a host in need of treatment, wherein said

Applicant: Michael EISENHUT et al.
Application No. 09/781,980
Attorney Docket No. 2502498-991110
(formerly 41443)

treatment is a cancer treatment.

18. (Cancel) The method according to claim 17, wherein said treatment is cancer treatment, viral disease treatment, inflammatory process treatment, asthmatic disease treatment, central nervous system disease treatment and cardiovascular disease treatment.